DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1955)

Asthma | Access and Reimbursement | US | 2016

Asthma | Access and Reimbursement | US | 2016

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics with novel mechanisms of action and with several more biologics in late-stage development for asthma, this market is set to undergo substantial change. Indeed, the influx of costly new biologics and the onset of generic competition, including biosimilars, will make prescribers’ choice of therapy and payer decisions on reimbursement more and more complex. Marketers will struggle to gain favorable formulary position and physician uptake, while health plans try to contain drug-related healthcare spend. In Asthma | Access & Reimbursement | US, we present key insights from U.S. physicians and payers on the prescribing and reimbursement of current asthma therapies, and we explore the reimbursement dynamics that promote or restrict market access of current and emerging agents.

Already a Client? Log in to access this report.

  • Pub Date: May 2016

Purchase Report

Recent reports:
You may also be interested in: